China Pharma Holdings (CPHI) Gross Profit (2010 - 2026)

China Pharma Holdings (CPHI) has reported Gross Profit for 17 consecutive years, with $83566.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 196.04% year-over-year to $83566.0; the trailing twelve-month figure through Jun 2026 stood at $460174.0 (up 150.94% YoY), and the FY2025 full-year result was -$131950.0, up 93.35% from the prior year.
• Gross Profit fell to $83566.0 in Q2 2026 per CPHI's latest filing, from $285487.0 in the prior quarter.
• Across five years, Gross Profit topped out at $285487.0 in Q1 2026 and bottomed at -$1.0 million in Q2 2024.
• Historically, Gross Profit has averaged -$140197.0 across 5 years, with a median of -$136908.5 in 2022.
• The sharpest annual moves came in 2024 and 2026: Gross Profit slumped 592.34% in 2024, then surged 309.82% in 2026.
• Over 5 years, Gross Profit stood at $42682.0 in 2022, then tumbled by 285.46% to -$79158.0 in 2023, then sank by 102.87% to -$160589.0 in 2024, then jumped by 193.89% to $150775.0 in 2025, then sank by 44.58% to $83566.0 in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $83566.0, $285487.0, and $150775.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.